204 related articles for article (PubMed ID: 36124593)
21. Identification of seven long noncoding RNAs signature for prediction of biochemical recurrence in prostate cancer.
Shao N; Zhu Y; Wan FN; Ye DW
Asian J Androl; 2019; 21(6):618-622. PubMed ID: 30860081
[TBL] [Abstract][Full Text] [Related]
22. A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma.
Liu J; Tan Z; Yang S; Song X; Li W
Aging (Albany NY); 2022 Sep; 14(17):7170-7185. PubMed ID: 36103249
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive analysis of the biological functions of endoplasmic reticulum stress in prostate cancer.
Cen S; Jiang D; Lv D; Xu R; Hou J; Yang Z; Wu P; Xiong X; Gao X
Front Endocrinol (Lausanne); 2023; 14():1090277. PubMed ID: 36967783
[TBL] [Abstract][Full Text] [Related]
24. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
Luo C; Chen J; Chen L
Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
[TBL] [Abstract][Full Text] [Related]
25. Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer.
Zhang G; Luo Y; Dong W; Zhong W
Comput Math Methods Med; 2022; 2022():8233840. PubMed ID: 35516457
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value and potential mechanism of Matrix Metalloproteinases among Prostate Cancer.
Geng X; Chen C; Huang Y; Hou J
Int J Med Sci; 2020; 17(11):1550-1560. PubMed ID: 32669958
[No Abstract] [Full Text] [Related]
28. Identification and validation of a six immune-related gene signature for prediction of biochemical recurrence in localized prostate cancer following radical prostatectomy.
Luan J; Zhang Q; Song L; Wang Y; Ji C; Cong R; Zheng Q; Xu Z; Xia J; Song N
Transl Androl Urol; 2021 Mar; 10(3):1018-1029. PubMed ID: 33850736
[TBL] [Abstract][Full Text] [Related]
29. Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.
Bian Z; Huang X; Chen Y; Meng J; Feng X; Zhang M; Zhang L; Zhou J; Liang C
Int J Med Sci; 2021; 18(1):284-294. PubMed ID: 33390797
[TBL] [Abstract][Full Text] [Related]
30. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
Liu J; Xu W; Li S; Sun R; Cheng W
Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
[No Abstract] [Full Text] [Related]
31. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
32. A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer.
Shao N; Tang H; Mi Y; Zhu Y; Wan F; Ye D
Oncoimmunology; 2020 Jun; 9(1):1762473. PubMed ID: 32923125
[TBL] [Abstract][Full Text] [Related]
33. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
34. Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients.
Yan Z; Gao Y; Yu J; Shen Z; Bu X
J Immunol Res; 2022; 2022():8972730. PubMed ID: 35647198
[TBL] [Abstract][Full Text] [Related]
35. A reliable transcriptomic risk-score applicable to formalin-fixed paraffin-embedded biopsies improves outcome prediction in localized prostate cancer.
Rade M; Kreuz M; Borkowetz A; Sommer U; Blumert C; Füssel S; Bertram C; Löffler D; Otto DJ; Wöller LA; Schimmelpfennig C; Köhl U; Gottschling AC; Hönscheid P; Baretton GB; Wirth M; Thomas C; Horn F; Reiche K
Mol Med; 2024 Feb; 30(1):19. PubMed ID: 38302875
[TBL] [Abstract][Full Text] [Related]
36. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
Chen L; Zhang M; Zhou J; Zhang L; Liang C
Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
[TBL] [Abstract][Full Text] [Related]
37. A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer.
Ke ZB; You Q; Sun JB; Zhu JM; Li XD; Chen DN; Su L; Zheng QS; Wei Y; Xue XY; Xu N
Front Cell Dev Biol; 2021; 9():774625. PubMed ID: 35071228
[No Abstract] [Full Text] [Related]
38. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer.
Li H; Gu J; Tian Y; Li S; Zhang H; Dai Z; Wang Z; Zhang N; Peng R
Front Immunol; 2022; 13():982628. PubMed ID: 36325340
[TBL] [Abstract][Full Text] [Related]
39. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
40. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
